Studies
PROBE-PD
Funding agency: Michael J. Fox Foundation and CNPq
The epidemiology of Parkinson’s disease is still under-studied in Brazil, which hampers health service planning, implementation of public policies, and research activities. Our objective is to conduct a population-based study, in which all individuals over 60 years old living in certain localities in the cities of Veranópolis (RS), Belém (PA), Candangolândia (DF), and Jacobina (BA) will be evaluated. Besides the prevalence of Parkinson’s disease in four distinct regions of Brazil, we also study prodromal forms of the disease and associations with environmental exposure and lifestyle. ClinicalTrials.gov ID: NCT05677529. Website: https://probe-pd.org/
MOSAIC-PD
Funding agency: Michael J. Fox Foundation
Parkinson’s disease exhibits significant heterogeneity in its clinical presentation and pathophysiological aspects, complicating patient treatment and counseling, as well as the conduct of clinical trials and other studies. This project aims to employ artificial intelligence algorithms to suggest possible subtypes of Parkinson’s disease based on genomic, transcriptomic, and neuroimaging information. We hope to contribute to the scientific community by better defining the subtypes of the disease.
Monogenic Forms of Parkinson’s Disease
Funding agency: Fapergs and CARD/NIA/NIH
Around 10% of patients with Parkinson’s disease have monogenic forms, meaning that a mutation in a single gene is sufficient and necessary for the disease to occur. Our project selects subjects with the disease for broad genetic analysis to determine the frequency of disease-causing genes in our population.
LARGE-PD
Funding agency:
Our center is a collaborating member of the international LARGE-PD consortium, which seeks to determine risk genes for the development of sporadic Parkinson’s disease. As a result, we hope to contribute to a better understanding of the genetic architecture of the disease in our country, which could lead to risk determination tools for counseling and selection for clinical trials, as well as the potential for better understanding of the disease’s pathophysiology and the development of new treatment modalities.
Address
2350 Ramiro Barcelos Street
Porto Alegre – RS, Brazil
Phone
+55 51 9881 1755